Balyasny Asset Management

Balyasny Asset Management’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Balyasny Asset Management’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-871,409	Closed	-$5.24M	–	3496
2022 Q4	$5.24M	Buy	+871,409	New	+$4.76M	0.02%	1001
2022 Q3	–	Sell	-102,333	Closed	-$611K	–	3566
2022 Q2	$611K	Buy	102,333 +58,197	+132%	+$298K	﹤0.01%	1917
2022 Q1	$206K	Buy	+44,136	New	+$132K	﹤0.01%	2012
2019 Q2	–	Sell	-218,273	Closed	-$212K	–	1887
2019 Q1	$212K	Sell	218,273 -704,382	-76%	-$742K	﹤0.01%	1347
2018 Q4	$677K	Buy	922,655 +622,655	+208%	+$1.02M	0.01%	1017
2018 Q3	$648K	Sell	300,000 -12,916	-4%	-$32K	﹤0.01%	1303
2018 Q2	$1.56M	Buy	+312,916	New	+$1.37M	0.01%	1012

Other funds holding CTIC

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return

Marshall Wace London, United Kingdom $93.4B AUM 35.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return